Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hong-Ling Peng

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Oncotarget|February 5, 2016
A TET2 rs3733609 C/T genotype is associated with predisposition to the myeloproliferative neoplasms harboring JAK2(V617F) and confers a proliferative potential on erythroid lineagesXiao-hui Shen, Nan-nan Sun, Ya-fei Yin, et al.
Plos One|September 3, 2011
Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalingsJian feng Zhu, Zi jian Li, Guang sen Zhang, et al.
Blood Advances|September 18, 2024
Asymptomatic multicentric Castleman disease: a potential early stage of idiopathic MCDLu Zhang, Qin-Hua Liu, Hui Zhou, et al.
The Lancet Regional Health. Western Pacific|June 7, 2023
A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteriaLu Zhang, Yu-Jun Dong, Hong-Ling Peng, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Oncotarget|February 5, 2016
A TET2 rs3733609 C/T genotype is associated with predisposition to the myeloproliferative neoplasms harboring JAK2(V617F) and confers a proliferative potential on erythroid lineagesXiao-hui Shen, Nan-nan Sun, Ya-fei Yin, et al.
Plos One|September 3, 2011
Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalingsJian feng Zhu, Zi jian Li, Guang sen Zhang, et al.
Blood Advances|September 18, 2024
Asymptomatic multicentric Castleman disease: a potential early stage of idiopathic MCDLu Zhang, Qin-Hua Liu, Hui Zhou, et al.
The Lancet Regional Health. Western Pacific|June 7, 2023
A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteriaLu Zhang, Yu-Jun Dong, Hong-Ling Peng, et al.
Pageof 4